PreveCeutical Provides Update on Second Phase of Scorpion Venom-Derived Peptide Program
Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to provide an update on its three phase, scorpion venom-derived peptide research and development program (the “Program”), which consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean Blue Scorpion venom, which are a highly complex mixture of peptides, enzymes, mucoproteins, free amino acids, lipids and other biological substances. Ultimately, this Program is expected to enable the Company to generate Nature Identical™ peptide therapeutics that are intended to treat, regulate and prevent cancer progression. PreveCeutical’s initial focus will be on targeting glioblastoma, a highly-aggressive form of brain cancer.
The Company has completed Phase 1 of the Program successfully (see news releases dated August 11, 2017 and January 24, 2018). The successful completion of Phase 1 yielded promising results, as PreveCeutical’s research team, led by Dr. Harendra Parekh, identified eight peptides being of a size and nature that will allow PreveCeutical to re-design and synthesise them, making them candidates for the Company’s future Nature Identical™ peptide therapeutics.
The Company has commenced Phase 2 of the Program, which involves re-designing the peptides, with the goal of enhancing their biostability, while maintaining their potency during screening against well-characterised and defined targets associated with brain cancer. To achieve this goal, the Company’s research team is using state-of-the-art computer technology for its in-silico modelling and docking studies, against known brain cancer targets (e.g. Matrix metalloproteinases) to determine the structural features and amino acid sequences critical to their binding.
As peptide sequences are generated from the Company’s modelling and docking studies, the Company will begin to re-engineer the identified peptides and to employ its proprietary peptide linker technology to conserve the peptides’ structural features responsible for binding and other critical activities.
Each novel, uniquely designed Nature Identical™ peptide candidate will then be purified and fully characterised. After generating a comprehensive library of highly stable Nature Identical™ peptide candidates, the Company will enter Phase 3, and begin to screen the peptides in cell-based glioblastoma models.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel drug delivery program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). In addition, the Company has recently launched a cannabis division responsible for bringing an array of high-quality, medicinal cannabis-based products to market.
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. Scorpion venoms have a history of use in traditional medicine in African and Asian countries to treat various diseases and chronic pain. This product is available on the Company’s website.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman, CEO and President
For further information, please contact:
Director of Corporate Communications & Investor Relations
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the ability of the Company to re-design and synthesize target peptides, the success of the in silico screening and its application to in vivo or in vitro screening models and the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, but not limited to, the state of the financial markets for the Company’s equity securities and the inability of the Company to successfully meet its research milestone, execute its proposed business plans and obtain the financing required to carry out its planned future activities, and difficulties in research and development activities, generally. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements